Oxford BioMedica PLC (OXB)
Industry Biotechnology
This stock can be held in an Investment ISA, SIPP and Investment Account
Sell
555.00p
Buy
560.00p
-9.00p (-1.58%)
Prices updated at 02 Apr 2026, 16:35 BST
| Prices minimum 15 mins delay
Prices in GBX
Oxford BioMedica PLC is a biopharmaceutical company based in the United Kingdom. It develops gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Income statement
Year | 2024 | 2025 |
|---|---|---|
| 129m | 169m | |
| 53m | 66m | |
| -44m | -33m | |
| -33.78 | -19.53 | |
| -43m | -30m | |
| -14m | 2m | |
| Sales, General and administrative | 29m | 37m |
| Interest expenses | 11m | 15m |
| Provision for income taxes | 1m | -1m |
| Operating expenses | 97m | 99m |
| Income before taxes | -47m | -32m |
| Net income available to common shareholders | -43m | -30m |
| -0.4175 | -0.2692 | |
| Net interest income | -7m | -9m |
| Advertising and promotion | - | - |
| Net investment income, net | -621,000 | - |
| Realised capital gains (losses), net | - | - |
| Total benefits, claims and expenses | - | - |
| Earnings per share (diluted) | -0.4175 | -0.2692 |
| Free cash flow per share | -0.7146 | -0.1158 |
| Book value/share | 0.6253 | 0.271 |
| Debt equity ratio | 1.829068 | 1.555306 |
Balance sheet
Year | 2024 | 2025 |
|---|---|---|
| Current assets | 133m | 186m |
| Current liabilities | 58m | 84m |
| Total capital | 97m | 133m |
| Total debt | 109m | 148m |
| Total equity | 57m | 91m |
| Total non current liabilities | - | - |
| Loans | 40m | 41m |
| Total assets | 232m | 326m |
| Total liabilities | - | - |
| Cash and cash equivalents | 61m | 97m |
| Common stock | 106m | 121m |
Cash flow
Year | 2024 | 2025 |
|---|---|---|
| Cash at beginning of period | 104m | 61m |
| Cash dividends paid | - | - |
| -58m | -4m | |
| Investments (gains) losses | 6m | -6m |
| 61m | 97m | |
| Net income | - | - |
| -51m | 507,000 | |
| -7m | -5m |
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.
